絞り込み

16645

広告

新型ウイルス 封鎖から1か月 先行きの見えない街 中国 武漢 (NHK)

新型コロナウイルスの感染が広がっている中国で状況が最も深刻な湖北省武漢では、事実上、街が封鎖される措置がとられてから23日で1か月になります。住民は外出を厳しく...

  1. クルーズ船対応の医師や看護師は検査対象外...
  2. [企業] DBV社のピーナツアレルギー貼...
  3. 下船後の感染初確認 健康状態把握続ける ...
  4. 白亜紀末の生物大量絶滅は巨大隕石落下直後...

ニュース一覧

Relapse- and immunosuppression-free survival after hematopoietic stem-cell transplantation: How can we assess treatment success for complex time-to-event endpoints?

著者 Bluhmki T , Schmoor C , Finke J , Schumacher M , Socié G , Beyersmann J この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)

Full Text Sources

In most clinical oncology trials, time-to-first-event analyses are used for efficacy assessment, which do often not capture the entire disease process. Instead, the focus may be on more complex time-to-event endpoints, as e.g. the course of disease after the first event or endpoints occurring multiply post randomization. We propose "relapse-free and immunosuppression-free survival" (RIFS) as an innovative and clinically relevant outcome measure for assessing treatment success after hematopoietic stem cell transplantation (SCT). To capture the time-dynamic relationship of multiple episodes of immunosuppressive therapy during follow-up, relapse, and non-relapse mortality, a multistate model is developed. The statistical complexity is that the probability of RIFS is non-monotonic over time; thus, standard time-to-first-event methodology is inappropriate for formal treatment comparisons. Instead, a generalization of the Kaplan-Meier method is used for probability estimation, and simulation-based resampling is suggested as a strategy for statistical inference. We reanalyze data from a recently published phase III trial in 201 leukemia patients after SCT. The study aimed at evaluating long-term treatment success of standard GvHD prophylaxis plus a pre-transplant anti-human-T-lymphocyte immunoglobulin compared to standard prophylaxis alone. Results suggest that treatment increases the long-term probability of RIFS by approximately 30% during the entire follow-up period, which complements the original findings. This article highlights the importance of complex endpoints in oncology. They give deeper insight into the treatment and disease process over time. Multistate models combined with resampling are highlighted as a promising tool to evaluate treatment success beyond standard endpoints. Example code is provided in the Supplementary Materials.
PMID: 31927103 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード